Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR7 | P34969 | 5/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253257 | 1.00 | HTR2C (0.47) | HTR2CHTR2AHTR7PRMT5PRMT1 | |
| SCHEMBL29611924 | 0.81 | HTT (0.50) | HTR2CHTR2A | |
| SCHEMBL19760709 | 0.81 | HTT (0.50) | HTR2CHTR2A | |
| SCHEMBL20912832 | 0.81 | HTT (0.50) | HTR2CHTR2A | |
| SCHEMBL7253255 | 0.80 | PRMT5 (0.48) | HTR2CHTR2AHTR7PRMT5PRMT1 | |
| SCHEMBL24142902 | 0.78 | HTR7 (0.63) | HTR2CHTR2AHTR7PRMT5PRMT1 | |
| SCHEMBL25521345 | 0.76 | HTR2C (0.43) | HTR2CHTR2APRMT5 | |
| SCHEMBL26103410 | 0.76 | HTR2C (0.43) | HTR2CHTR2APRMT5 | |
| SCHEMBL25521335 | 0.76 | HTR2C (0.63) | HTR2CHTR2APRMT5 | |
| SCHEMBL7253595 | 0.76 | HTR2C (0.55) | HTR2CHTR2AHTR7PRMT5PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR2C 127/4885HTR2A 425/4885HTR7 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.